argenx SE (ARGX)
ARGX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$802.64
-1.19% on the day
Market cap
$49.8B
Large cap
Revenue
No annual revenue filed since the period ending 2023-12-31
Net income
No annual revenue filed since the period ending 2023-12-31
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ARGX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Netherlands |
| IPO year | 2017 |
| SEC CIK | 0001697862 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | P7 |
Financials
No annual revenue filed since the period ending 2023-12-31.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2023-07-20 |
| Latest annual report | 20-F | 2026-03-19 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-08 |
Source: SEC EDGAR submissions feed, 293 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.5% |
| 1 month | -16.2% |
| 3 months | -4.3% |
| Year to date | -2.3% |
| 1 year | +2.7% |
| From 52-week high | -22.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RVMD | Revolution Medicines Inc. | $188.44 | -2.84% | $40.4B |
| BIIB | Biogen Inc. | $228.90 | -0.22% | $33.8B |
| MRNA | Moderna Inc. | $216.25 | +1.17% | $86.3B |
| BNTX | BioNTech SE American Depositary Share | $89.01 | -7.13% | $22.4B |
| EXEL | Exelixis Inc. | $59.51 | -0.52% | $14.7B |
| NBIX | Neurocrine Biosciences Inc. | $135.13 | -4.41% | $13.7B |
| GILD | Gilead Sciences Inc. | $147.92 | -1.67% | $183.4B |
| HALO | Halozyme Therapeutics Inc. | $109.62 | -1.31% | $12.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier